



TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

Date: 07/10/2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Scrip Code: 539519

Subject: Outcome of the Meeting of the Board of Directors held on Wednesday, 07th October, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of **Tavexia Lifecare Limited** (“Company”) was duly convened and held on **Wednesday, 07th October, 2026**.

The Board of Directors, inter alia, considered and deliberated upon the following matters:

1. Approval of Valuation and Due Diligence Report and Proposed Acquisition of Meyonex Pharmaceuticals Limited

The Board was apprised of and reviewed the **Valuation Report and Due Diligence Report** in relation to the proposed acquisition of up to **60% of the equity share capital of Meyonex Pharmaceuticals Limited**, an unlisted public company having CIN: **U74120MH2015PLC261024**.

After detailed consideration and deliberation of the Valuation Report and the developments in relation to the proposed acquisition, the Board **took note of and approved the said Valuation Report and Due Diligence Report**.

2. Proposed Acquisition of Meyonex Pharmaceuticals Limited

The Board further discussed and deliberated upon the developments in relation to the proposed acquisition of **up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited**, an unlisted public company having CIN: **U74120MH2015PLC261024**.

The Board took note of the progress made pursuant to its earlier meeting held on **Monday, 07th September, 2026**, wherein the Board had discussed the proposal for acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited.

The Board, after due deliberations and consideration of all relevant aspects, **approved the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited**, subject



TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

to necessary approval if any, wherever required, and such other statutory, regulatory, governmental, contractual and other approvals, consents and permissions as may be applicable, and subject to execution of definitive agreements and fulfilment of the terms and conditions contained therein.

Based on the Valuation Report and the discussions held, the Board approved the proposed acquisition of 60% of the post-allotment equity share capital of Meyonex by way of subscription to fresh equity shares to be issued and allotted by Meyonex to the Company, subject to obtaining the approval of the shareholders of the Company, wherever required, and such other statutory, regulatory, governmental, contractual and other approvals, consents and permissions as may be applicable, and subject to execution of definitive agreements and fulfilment of the terms and conditions contained therein.

The proposed shareholding structure pursuant to the proposed allotment is as follows:

Particulars	Equity Shares	Percentage
Existing paid-up equity shares of Meyonex Pharmaceuticals Limited	1,39,98,120	40.00%
Fresh equity shares to be issued and allotted to Tavexia Lifecare Limited	2,09,97,180	60.00%
Total equity shares after proposed allotment	3,49,95,300	100.00%
Post-allotment holding of Tavexia Lifecare Limited	2,09,97,180	60.00%
Existing shareholders' holding	1,39,98,120	40.00%

Accordingly, upon completion of the proposed fresh issue and allotment, the Company shall hold 2,09,97,180 equity shares, representing 60% of the total post-allotment paid-up equity share capital of Meyonex Pharmaceuticals Limited, while the existing shareholders of Meyonex Pharmaceuticals Limited shall collectively hold 1,39,98,120 equity shares, representing the remaining 40%.

The Board further approved the issue price of ₹32/- (Rupees Thirty-Two only) per equity share, based on the valuation undertaken in relation to Meyonex Pharmaceuticals Limited.

Accordingly, the total consideration/investment proposed to be made by Tavexia Lifecare Limited towards subscription to the aforesaid 2,09,97,180 fresh equity shares of Meyonex Pharmaceuticals Limited shall be ₹67,19,09,760/- (Rupees Sixty-Seven Crore Nineteen Lakh Nine Thousand Seven Hundred Sixty only).

The Board further noted and approved that the consideration for the proposed acquisition/investment shall be made entirely in cash mode only.

The proposed transaction shall be completed in one or more tranches by company, subject to the execution of definitive agreements and completion of all applicable conditions precedent, including such statutory, regulatory, governmental, contractual and other approvals, consents and permissions as may be required.

3. Fund Raising for Financing the Proposed Acquisition

The Board further considered the funding requirements for making the proposed investment of ₹67,19,09,760/- towards subscription to the fresh equity shares of Meyonex Pharmaceuticals Limited.



TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

In this regard, the Board approved in principle that the Company may raise funds, as may be required, for financing the consideration payable towards the proposed investment/acquisition, by way of issue of such securities as may be permitted under applicable laws, including equity shares, warrants, debentures/debt securities or any other securities on Preferential basis of Right Issue basis, through such mode and on such terms and conditions as may be determined by the Board, subject to obtaining such necessary approvals and other statutory, regulatory and other approvals as may be applicable.

The Board further noted that the quantum, size, nature, type, issue price, timing, mode and other terms and conditions of the proposed fund raising shall be considered and determined by the Board at a subsequent meeting, based on the funding requirement, valuation, prevailing market conditions and applicable legal and regulatory requirements.

The Board authorised the designated representatives of the Company to undertake such preliminary discussions, evaluations and preparatory actions as may be necessary in connection with the proposed fund raising and the proposed investment/acquisition, subject to the approval of the Board wherever required.

The Board further authorised the designated representatives of the Company to negotiate, finalise and execute the requisite agreements, documents, applications and other writings and to do all such acts, deeds, matters and things as may be necessary or incidental for giving effect to the above decisions, subject to applicable approvals.

The Board also considered and transacted such other business matters as were placed before it with the permission of the Chairperson.

The meeting commenced at **9:30 PM** and concluded at **10:25 PM**.

The above is for your information and record.

Thanking You,

Yours Faithfully,

For Tavexia Lifecare Limited
(Formerly Sattva Sukun Lifecare Limited)

Poonam Rani
Digitally signed
by Poonam Rani
Date: 2026.10.07
22:32:59 +05'30'

Poonam Rani
Company Secretary



TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

Disclosure regarding Proposed Acquisition of shares of Meyonex Pharmaceuticals Limited , pursuant to Regulation 30 of the SEBI Listing Regulations

Sr. No	Particulars	Details
1	Name of the Target Entity	Meyonex Pharmaceuticals Limited
2	CIN of the Target Entity	U74120MH2015PLC261024
3	Whether the acquisition is related to promoter/promoter group/group companies	No. The proposed acquisition is not related to the promoter/promoter group/group companies of Tavexia Lifecare Limited.
4	Industry to which the entity being acquired belongs	Pharmaceuticals
5	Objects and effects of acquisition	The proposed acquisition is being undertaken with the objective of acquiring a controlling stake in Meyonex Pharmaceuticals Limited and expanding the Company's presence and business operations in the pharmaceutical sector.
6	Brief details of any governmental or regulatory approvals required for the acquisition	The proposed acquisition shall be subject to such statutory, regulatory and other approvals as may be applicable.
7	Indicative time period for completion of the acquisition	The acquisition is proposed to be completed subject to satisfactory completion of due diligence, valuation, negotiations, execution of definitive agreements and fulfilment of applicable statutory and regulatory requirements and other customary conditions.
8	Consideration – whether cash consideration or share swap or any other form	The consideration and mode of payment shall be in cash pursuant to the valuation and negotiations and shall be specified in the definitive agreements.
9	Cost of acquisition and/or the price at which the shares are acquired	The Cost of acquisition is ₹67,19,09,760/-.
11	Brief background about the entity acquired in terms of products/line of business, date of incorporation, history of last 2 years turnover, country in which it operates and any other significant information	Meyonex Pharmaceuticals Limited is an unlisted public company engaged in the pharmaceutical sector. The company is incorporated in India and has CIN U74120MH2015PLC261024. Date of incorporation: 17 January 2015 Turnover: F.Y. 2024 Rs. 13,32,07,50,000/- F.Y. 2025 Rs. 10,79,21,50,000/-
12	Country of operation	India
13	Registered Office	PLOT NO C - 13 MIDC Tarapur Palghar, Thane, Maharashtra, India, 401506
15	Face value of Share	₹10/- per equity share
16	Paid-up Capital (Rs)	₹20,00,00,000/-



TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

17	Turnover of the Target Entity for the last 3 financial years	₹13,99,81,200/-
18	Whether the acquisition would fall within related party transaction(s)	Not applicable
19	Whether the promoter/promoter group/group companies have any interest in the entity being acquired	Not applicable
20	Whether the acquisition is a slump sale	Not applicable.

Poonam Rani  Digitally signed by Poonam Rani
Date: 2026.10.07 22:33:43 +05'30'